Disparity in treatment patterns among Medicare beneficiaries diagnosed with chronic lymphocytic leukemia: an analysis of patient and contextual factors
AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors
2023•CLINICAL DATA
Frentzas, Sophia | Journal for ImmunoTherapy of Cancer
Updated efficacy & safety of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed/refractory Waldenström macroglobulinemia (WM): Ongoing phase 1 CaDAnCe-101 study results
This website is intended exclusively for healthcare professionals and is provided for scientific exchange and educational purposes only. It is not intended for patients or the general public and does not constitute advertising, promotional activity or medical advice.
Content may include information about products, indications or uses that are not approved in all countries or regions, and may be subject to local regulatory requirements.
By continuing, you confirm that you are a healthcare professional and acknowledge the above.
You are now leaving the website
This link is provided for information purposes only. You’ll be leaving beonemedaffairs.com and accessing a third-party website over which [BeOne Medicines | GmbH] has no control or influence.
This link will take you to a third-party website outside of beonemedaffairs.com.
[BeOne Medicines | GmbH] has no control over this website and makes no representations regarding its content or availability in your location. [BeOne Medicines | GmbH] declines any responsibility for third-party information, data usage policies, or personal data processing.
By proceeding, you acknowledge that you are part of the intended audience of the third-party website and confirm your compliance with applicable laws.
Do you want to leave beonemedaffairs.com
You are now leaving the the website beonemedaffairs.com and entering another BeOne website with different terms of use. Information included on this website may not be specific to your country. Click Continue to proceed
